Stevens 1991.

Methods	Prevention study in USA Loss to follow‐up: Fluconazole ‐ 3/12 (25%) Placebo ‐ 5/13 (38%) Analysis: ITT
Participants	Inclusion criteria: at least 18 years of age; previous history of at least one episode of thrush; AIDS or ARC Exclusion criteria: less than 18 years of age; pregnant or lactating; women not observing accepted birth control measures; history of allergy to azoles; inability to take oral drugs; serum creatinine > 221 micromol/L; receiving barbiturates, anticoagulants, hypoglycaemic drugs, immunotherapy, rifampicin or its derivatives, concurrent antifungal agents. Diagnosis confirmed: yes ‐ KOH preparation and culture 25 patients enrolled 12 ‐ fluconazole therapy 13 ‐ placebo
Interventions	Fluconazole 100mg tablets once per day Placebo once daily Duration: 12 weeks
Outcomes	Relapse of thrush defined as the presence of white or rarely red oropharyngeal patches that when smears are examined produced the characteristic microscopic appearance of C Albicans or that on culture yielded C albicans or were positive in both assays. Adverse events: increased liver function tests, GIT symptoms.
Notes	Ethics: ethics approval obtained from IRb committee for protection of human subjects, Santa Clara Valley Medical Centre and California Institute for medical research, San Jose; informed consent obtained
Risk of bias
Bias	Authors' judgement	Support for judgement
Adequate sequence generation?	Unclear risk	Method of sequence generation not reported
Allocation concealment?	Unclear risk	Not reported
Blinding? All outcomes	Low risk	Double‐blind: patients, investigators and caregivers.
Incomplete outcome data addressed? All outcomes	Low risk	ITT